Turn.bio Announces the Preliminary Results from a CAR T Cell Study
Turn.bio announced that their proprietary cellular reprogramming technique was able significantly increase in vitro the proliferative potential and cytotoxic potency of pre-manufactured CAR T cells.
Turn.bio has released preliminary results of its ongoing trial. The announcement was made at the New Frontiers of RNA Nanotherapeutics Conference at Houston Methodist Research Institute by Prof. Vittorio Sessagno, the co-founder of the company. These results demonstrate that the proprietary Epigenetic reprogramming of aging (ERA) technology of the company greatly increases the fitness and effectiveness of CAR T cells. CAR-Ts are used widely in modern immunotherapy.
T-cell exhaustion can be a serious problem.
Source:
Turn.bio Announces Preliminary Results of a CAR-T Cell Study
